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ABSTRACT 
Joint prostheses chronic infection requires surgical removal of the implant, in order to eradicate the infection process. The 
Polymethylmethacrylate (PMMA) bone cement is a good carrier for the sustained antibiotic release at the site of infection. PMMA 
cements pre-loaded with antibiotics are utilized for prophylaxis, primary surgical procedure and the treatment  of prosthetic joint 
infections. The mechanical and functional characteristics of the spacers allow a good joint range of motion, weight-bearing in selected 
cases and a sustained release of antibiotic at the site of infection. These drug delivery systems offer the advantage of local release of high 
antibiotic concentrations, which considerably exceed those obtained after systemic administration. Nowadays treatment with a preformed 
antibiotic loaded spacer can be considered a good option for joint prostheses infection maintaining joint function at the intermediate 
stage in two-stage treatment. 
Keywords: Acrylic bone cement, joint Infection, Antibiotic spacer, Polymethyl methacrylate, Drugs delivery systems. 
1. INTRODUCTION 
  With the increasing mean age of the population, the 
prevalence of degenerative diseases such as osteoarthritis is 
steadily rising. Implanted devices are highly susceptible to 
bacterial infection. Patient related risk factors for periprosthetic 
joint  infection include male gender, obesity, diabetes mellitus, 
posttraumatic arthritis, rheumatoid arthritis, and fracture around 
the knee [1,  2]. The arthroplasty itself remains a lifelong risk 
factor for acquiring periprosthetic joint infection through 
hematogenous seeding [3, 4]. The most frequent infecting agents 
are coagulase-negative staphylococci (in 13-36% of cases) and 
Staphylococcus aureus (21-25%) [5, 6, 7-9].  In the recent years 
the acrylic bone cement, sometimes abandoned unnecessarily for 
fixing prosthesis to the bone, seems a material still able to play 
new roles in orthopaedic  surgery. Experimental studies and 
clinical evidence are re-evaluating not only its use in prosthetic 
surgery, but also its use as a biomaterial able for drugs delivery 
systems, fractures’ support  synthesis  ("augmentation"), the 
construction of articulating spacers in the treatment of bone and 
joint in fections and tumors with future prospects to provide the 
substrate for modern bone substitutes. In this mini review we have 
screened  different databases, as PubMed, Google Scholar and 
Academic Search Complete, for articles published between 2000 
and 2014 concerning information about the use of   
polymethylmethacrylate (PMMA) in joint infections using the 
following search filter: ‘‘antibiotic spacer’’, ‘‘knee infection’’, 
‘‘hip infection’’ and ‘‘shoulder infection’’ that identified a total of 
4914 articles. They were combined into EndNote and reviewed 
manually in order to exclude repetitions and to select those 
specifically related to the argument; among the remaining 731 
pertinent articles case reports and articles referring to alternative 
options treatment were excluded. A total amount of 380 articles 
were found for inclusion based on the use of   
polymethylmethacrylate  (PMMA) antibiotic spacers in joint 
infections. Of these articles 19 concerning the filter ‘‘antibiotic 
spacer’’, 173 ‘‘knee infection’’, 174 ‘‘hip infection’’ and 14 
‘‘shoulder infection’’. 
 
2.  POLYMETHYLMETHACRYLATE (PMMA) AS ANTIBIOTIC CARRIER IN JOINT AND BONE 
INFECTIONS 
  Polymethylmethacrylate (PMMA) is a polymer of synthetic 
thermosetting capable of solidifying at room temperature [10, 11].  
Its use has been extended by the ophthalmological field 
(intraocular lenses) and dentistry (dental fillings) to the 
orthopaedic, known as acrylic bone cement, and used for the 
fixation of prosthetic implants and hip endoprosthesis according to 
Judet and Judet [12] in the early 1940s and for hip replacement 
according to Kiaer and Haboush in the 1950s [13, 14], up to 1960s 
Sir John Charnley, with modern hip replacement with acrylic 
cement [15]. The polymerization reaction leading to the formation 
of the bone cement  follows  a mechanism  of  redox  type. The 
monomer is by definition areactive moleculedue to the presence in 
its structure  of  unsaturated double bond  C=C [16].  Since  a 
considerable covalent bonds number that are established during 
the polymerization, it is estimated a total volumetric shrinkage of 
about  6-7%  [11,  17]. The polymerization reaction  is  an 
exothermic one. The heat  production studied  in vivo  showed a 
temperature between 40° and 56°, limit values  above which 
protein denaturation  and consecutive  biological damage 
(osteonecrosis) could occur [18].  For most of the cements, 
hardening time varies by a total of 10 to 20 min [19].  The 
observation of meticulous asepsis rules in the operating room [20, 
21], the application of systemic and local antibiotic treatment, by 
fixing  implants  with  antibiotic-loaded cement [22–23], have 
played a  significant role in reducing  infection rates  with an 
incidence between 0.5 and 3 % in primary hip and knee prosthesis 
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and a higher incidence in the case of revision procedure 
[25].Chronic infection of joint prostheses requires surgical 
removal of the implant, in order to eradicate the infectious process 
[20, 24]. The procedure can be performed in one stage [26] or in 
two stages [27, 28]. The use of antibiotic loaded cement (ALC) in 
the form of spacers during the interval period to deliver antibiotics 
locally has become popular as it has increased rates of infection 
control achieving up to 95% in several studies [28-31]. A number 
of papers have established the capability of ALC to deliver a much 
greater local concentration of antibiotic than is possible by 
systemic therapy [32-36]. Recent studies [37] suggest that the 
ALC may remove the need for systemic antibiotics in the interval 
period, thus decreasing costs and morbidity.  The PMMA bone 
cement is found to be a good carrier for the sustained release of 
antibiotics at the site of infection [38, 39]. The aminoglycosides 
(gentamicin, tobramycin) are considered first choice antibiotics, 
due to their small size, broad spectrum of antimicrobial activity, 
excellent solubility in water, chemical and thermal stability, 
biocompatibility and low allergenicity [16]. 
  Polymethylmethacrylate cements pre-loaded with 
antibiotics, mainly gentamicin (G), are used for prophylaxis, 
primary surgical procedure and, more frequently, in the revision of 
prosthetic joint infections [40].  However,  due to the increasing 
resistance  of bacteria  to these antibiotics,  additional  antibiotics 
(vancomycin, clindamycin, daptomycin,  oxazolidinones, 
fluoroquinolones, peptides, etc.) were used in bone infections [41, 
42].  The vancomycin has physical and chemical characteristics 
similar to aminoglycosides, with some limitations regarding the 
difficulty of cement to polymerize if used in high doses and at low 
release period [32]. In the two stages revision surgery the 
replanting is delayed by a few months (2–5) during which an 
antibiotic-loaded cement spacer is placed in the prosthetic site [27] 
with two functions: a mechanical function, to avoid the shortening 
periarticular soft tissue, while maintaining the correct geometry of 
limbs, and a biological function, through local release of antibiotic 
in effective concentrations. Spacers can be prepared 
extemporaneously in the operating room by the surgeon or can be 
industrially  fabricated  spacers, that have mechanical and 
pharmacological standardized characteristics and a predetermined 
level of safety and efficacy [16, 43, 44].  The PMMA antibiotic 
spacers mainly utilized in Italy, and in our Hospital too, are those 
provided by TecresS.p.A., Sommacampagna, Verona, Italy. The 
hip preformed spacer, Spacer-G
®, has a structure in stainless steel 
AISI 316ESR, and is available in three different diameters of the 
head (46, 54, and 60 mm) and two lengths of the stem (153 and 
270 mm). The gentamicin concentration is 2.5%. Currently, there 
is also available with flat rod (Flat Stem Spacer-G
®) and 
industrially supplemented with vancomycin at a concentration of 
2.5% (Vancogenx Hip-Space
®). The knee pre-formed antibiotic-
loaded polymethylmethacrylate (PMMA) Spacer K
® is a device 
consisting of two articulating components, femoral and tibial. It is 
available in three  different sizes, and may be chosen intra-
operatory. The gentamicin concentration varies from 0.9 g for the 
small spacer size to 1.8 g for the largest implant. The shoulder 
preformed spacer, Spacer S
®, is provided with a head diameter of 
46 mm and a stem length of 125 mm; a total of 0.8 grams of 
gentamicin was added during manufacturing to the PMMA with a 
concentration of 2.8 % w/w. A central stainless steel cylindrical 
bar is completely surrounded by the acrylic bone cement layer, in 
order to improve the mechanical strength of the device.  The 
disadvantages of preformed mobile spacers include limitation in 
implant sizes and antibiotic dose, often allowing delivery of only a 
single antibiotic to which the organisms being treated might not be 
susceptible [45, 46]. Mobile spacers assembled in the operating 
room have the advantage of adjustable antibiotic dosing. 
Disadvantages of such spacers include additional time to construct 
the implant in the operating room, the higher risk of fractures due 
to cement heterogeneity and inconsistencies in mixing and the 
potential risk of toxicity when high doses of antibiotics are added 
to the cement [45, 46]. In different cases, S. aureus infection is the 
significant factor associated with treatment failure, along with 
retained  prosthesis and treatment with inappropriate antibiotics 
[47].  Because of the increasing resistance of staphylococci to 
gentamicin, surgeons commonly add antibiotics (off-label) to bone 
cement in the operating room according to microorganism 
susceptibility. Vancomycin is frequently used  because of its 
efficiency against MRSA and other Gram-positive cocci and 
anaerobes [4]. Bertazzoni Minelli et al [39] in 2004 observed that 
gentamicin (G) and vancomycin (V) were still present in explanted 
spacers after 3 to 9 months of permanence in situ; the residual 
drug concentrations showed great variability. In another article of 
2014 [4] Bertazzoni Minelli et al., found that the concentrations of 
G and V determined singly in joint fluids during the first 24 hours 
after spacer implantation were very high, stable, and bioactive. An 
interesting observation was that a good antimicrobial activity was 
achieved when the G:V ratio was at least 2:1, with high drug 
concentrations. The antibiotic added to the cement cannot exceed 
the limit of 10% concentration, in order to avoid a mechanical 
resistance decrease of the spacer [44, 48,49]. According to these 
considerations, it is impossible to establish an absolute value of 
antibiotic concentration to be added to bone cement [4]. In two-
stage revision procedure, temporary spacers made of antibiotic-
loaded PMMA represent a viable option for a chronically infected 
joint prosthesis [50, 54].  With the use of this specific device, in 
literature are reported good eradication rate ranging from 80 to 
93.3% [50-53]. Industrial production ensures procedure 
standardization eliminating the time necessary to intraoperative 
manufacturing, and spacer-related complications, such as 
dislocations and fractures, ranging from 3.3 to 17% [50-53]. 
According to shoulder antibiotic spacer, different case studies 
have still a low number of patients, but no recurrence of infection 
after spacer placement [55, 6], while recurrence rate in literature 
ranges from 0 to 40 % [49].  Gentamicin and Vancomycin may 
maintain their permanence and activity in the periprosthetic tissue 
for prolonged periods [56,  57]. The removal of the temporary 
device reduces the risk of release of sub-therapeutic drug 
concentrations from biomaterial devices into the surrounding 
tissue and the risk of resistance in wound-site bacteria [39]. 
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3. CONCLUSION 
  The  PMMA based  drug delivery systems offer the 
advantage of local release of high antibiotic concentrations, which 
considerably exceed those obtained after systemic administration 
(for 4 to 6 weeks).Nowadays treatment with a preformed antibiotic 
loaded spacer can be considered a good option, with the aim of 
controlling the pain, maintaining a better condition of the soft 
tissues, sufficient muscle trophism and an easier implantation of 
the definitive prosthesis. The success of the antibiotic spacer must 
be linked to the fact that without drainages, the local antibiotic 
concentrations remain very high, exerting their antimicrobial 
effect in the infection site and favouring drug penetration into the 
surrounding tissues [4]. The preparation of the bone cements, its 
properties, type and concentrations of different antibiotics mixed 
with PMMA, patient characteristics, and the pathogens involved 
are all factors contributing to the clinical outcome.  Therefore 
further observations will be necessary for making a final decision 
on the validity of this method, as well as offering a starting point 
for new solutions. 
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